RT Journal Article
SR Electronic
T1 Pelvic Exenteration for Recurrent Endometrial Adenocarcinoma: A Retrospective Multi-institutional Study About 21 Patients
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 880
OP 884
DO 10.1097/IGC.0000000000000002
VO 24
IS 5
A1 Vito Chiantera
A1 Martina Rossi
A1 Pierandrea De Iaco
A1 Christardt Koehler
A1 Simone Marnitz
A1 Valerio Gallotta
A1 Alessandro Pasquale Margariti
A1 Fabio Parazzini
A1 Giovanni Scambia
A1 Achim Schneider
A1 Giuseppe Filiberto Vercellino
YR 2014
UL http://ijgc.bmj.com/content/24/5/880.abstract
AB Objective The aim of our study was to evaluate morbidity, mortality, and long-term survival of patients who underwent pelvic exenteration (PE) with curative intent for recurrence of endometrial adenocarcinoma during a single decade.Methods We defined a cohort of 21 patients who met our inclusion criteria, referred to 4 cooperating gynecologic oncology settings in Germany and Italy between 2000 and 2011. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until the last follow-up or death.Results The median age was 66 years. A total of 42.9% of the patients had major complications, and a complete resection was achieved in 85.7% of the patients. A total of 71.4% of the patients had negative nodes. No patient died intraoperatively. The perioperative mortality, calculated within 30 days from PE, was 4.8%. The overall 5-year survival rate, evaluated using the Kaplan-Meier method, was 40%. For the subgroup with complete resection and negative lymph nodes, overall survival reached 60%.Conclusions Despite a high complication rate, PE for solitary pelvic recurrence of endometrial cancer yields a high rate of long-term survival.